We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Correction: Teva Purchasing Allergan’s Generic Line
Correction: Teva Purchasing Allergan’s Generic Line
July 28, 2015
Teva will pay $40.5 billion to acquire drugmaker Allergan’s generic division. Allergan will retain 50 percent of Teva’s future earnings for its generic Revlimid (lenalidomide) and will retain its biosimilar development programs. Drug Industry Daily erroneously reported Tuesday that Teva was purchasing the entire company.